The following news tips are based on abstracts or posters to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 June 2, 2008.
Abstract # 9075, 8 a.m. to noon on Monday, June 1, 2009
Antiparasitic drug is promising in animal studies of metastatic melanoma
Seth J. Orlow, M.D., Ph.D., the Samuel Weinberg Professor of Pediatric Dermatology and chairman of the Ronald O. Perelman Department of Dermatology and professor of cell biology and pediatrics.
A drug used to treat parasitic infections shows early promise in animal studies as a potential treatment for metastatic melanoma. Researchers from NYU Langone Medical Center report that the orally administered drug, mebendazole, inhibited the growth and progression of human melanoma tumors grafted in mice. The researchers observed in the animals a 72 percent reduction in tumor volume, the inactivation of a key protein that normally promotes melanoma survival and a concomitant 81 percent increase in cancer cells that were programmed to die. The researchers are now planning a clinical trial to investigate the appropriate dosing of the drug, a first step toward assessing the drug's effectiveness in patients with metastatic melanoma.
Abstract # 9006, 1:30 p.m. on Saturday, May 30, 2009
MicroRNAs may aid in prognosis of metastatic melanoma
Eva Hernando-Monge, Ph.D., assistant professor of pathology
Iman Osman, M.D., associate professor of dermatology and urology and director of the Interdisciplinary Melanoma Cooperative Group
Miguel F. Segura, Ph.D., postdoctoral fellow
Ongoing research at the NYU Cancer Institute suggests that micoRNAa genetic element that controls protein-coding genesmay be useful as a biomarker for melanoma. In the latest study, levels of a specific group of microRNAs were associated with longer survival among patients with metastatic melanoma and am
'/>"/>
| Contact: Dorie Klissas dorie.klissas@nyumc.org 212-404-3555 NYU Langone Medical Center / New York University School of Medicine Source:Eurekalert |